cisplatin + epirubicin + ifosfamide

The combination of cisplatin, epirubicin, and ifosfamide is a multi-agent chemotherapy regimen used primarily in the treatment of various sarcomas, including osteosarcoma and uterine sarcoma. This regimen leverages the distinct mechanisms of each agent to maximize antitumor activity: - Cisplatin is a platinum-based compound that forms DNA crosslinks, leading to apoptosis. - Epirubicin is an anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, resulting in DNA strand breaks. - Ifosfamide is an alkylating agent that induces crosslinking of DNA strands and cell death. This combination has demonstrated efficacy as neoadjuvant or adjuvant therapy in localized primary osteosarcoma[1], as well as activity in advanced or recurrent uterine sarcoma[3][4]. The regimen's toxicity profile includes notable risks for neutropenia but generally lacks severe cardiac toxicity when monitored appropriately[1].

Other names

IEPCLD-IEP